Stock Ratings / Health Care / LFMD / financials

AIRS (48) NAKA (22) ALPS (57) EUDA (39) ⌘ Pro Terminal →

LifeMD Inc. (LFMD) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.32 +4.04% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.33

LifeMD Inc. (LFMD) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $111.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.33 (+0.54%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 3.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LFMD)Realized 20D OHLCV Swing Band: ±11.9%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY LFMD SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (28% of score)

FRED Regime × Technicals: 7% of 52W Range • RSI-14 at 38.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (24% of score)

20D Institutional Volume Accumulation (±11.9% realized swing band)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk5/20 pts (-15 pt drag)

Balance-sheet & 10-K footnote risk deducts 15 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$2.63-11% Next Q

Q2 (-2Q)

Grade C-$2.34-9% Next Q

Q3 (-1Q)

Grade D$2.13+8.9% Next Q

Current

Grade D$2.32-6.1% Hist 90D α

Trajectory: C- (54) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LFMD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LFMD currently carries a cautious 46/100 (D) rating due to SEC 10-K Forensic Risk (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.82) and Max Pain ($2.44) forces dealer call-delta covering toward $6.26.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LFMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LFMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How LFMD Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$6.4M (3.3% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $152.5M

FY24

Rev $154.8M

FY25

Rev $194.1M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$194.1M	85.7%	-4%	-$11.2M	$6.4M	-26.2%
FY 2024	$154.8M	86.2%	-13.2%	$24.5M	$16.0M	-45%
FY 2023	$152.5M	85.7%	-9.5%	$17.8M	$8.8M	-26.2%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LFMD)

✓Walkthrough of LFMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LFMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -50.43%▼ DESCENDING CHANNEL

2026-10-30O $2.30H $2.35L $2.24C $2.32VOL 599.1K

RES: $2.87SUP: $1.99SMA50: $2.82SMA200: $3.66

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LFMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LFMD Butterfly Map → + Track LFMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +25.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LFMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LFMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LFMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LFMD)

Health Care Rank #455 of 1016 ⚔️ AIRS vs LFMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LFMD vs. AIRS, NAKA, ALPS, EUDA)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, LifeMD Inc. (LFMD) ranks #455 by composite RQD confidence (46/100, grade D) and #645 by equity capitalization ($111.8M). Within this direct 5-issuer industry benchmark cohort, LFMD leads on earnings valuation at N/A trailing P/E, while AIRS leads on capital efficiency and profitability with -7.0% ROIC and — gross margin. ALPS currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with LFMD at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LFMD ACTIVE LifeMD Inc.	D	46/100	—	85.7%	-26.2%	+4.04%	$111.8M	Benchmark Subject
AIRS AirSculpt Technologies Inc.	D	48/100	—	—	-7.0%	+15.97%	$120.4M	/airs-vs-lfmd →
NAKA Nakamoto Inc.	E	22/100	—	—	-31.6%	-3.51%	$126.2M	/naka-vs-lfmd →
ALPS ALPS Group Inc Ordinary Share	D+	57/100	—	—	—	-0.03%	$54.1M	/alps-vs-lfmd →
EUDA EUDA Health Holdings Limited	D-	39/100	—	43.9%	-35.0%	+1.31%	$46.4M	/euda-vs-lfmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000948320

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LifeMD Inc. (LFMD) reported GAAP revenue of $194.1M (+25.3% vs. FY2024 revenue of $154.8M , and +27.2% cumulative change since FY2023) , GAAP net income of -$11.2M, operating cash flow of $8.3M, and free cash flow of $6.4M (-60.1% YoY). On the balance sheet, LFMD closed FY2025 with $70.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$194.1M	-$11.2M	$8.3M	$6.4M	$70.4M	—
FY2024 (FY)	2024-12-31	$154.8M	$24.5M	$17.5M	$16.0M	$76.1M	—
FY2023 (FY)	2023-12-31	$152.5M	$17.8M	$8.8M	$8.8M	—	—

3. LFMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LFMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, LifeMD Inc. (NASDAQ: LFMD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.32 (+4.04% 1D, market cap $111.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, LFMD ranks #455 in composite RQD confidence.

How does LFMD compare to AIRS and NAKA in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), LFMD carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of 85.7%, and ROIC of -26.2%. By comparison, AIRS (AirSculpt Technologies Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -7.0%, cap $120.4M) and NAKA (Nakamoto Inc.) posts a E grade (22/100 RQD, P/E N/A, ROIC -31.6%, cap $126.2M). Among the 5-stock peer group, LFMD leads on earnings multiple (N/A) while AIRS leads on capital efficiency (-7.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LFMD?

Per LFMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000948320), LifeMD Inc. generated $194.1M in revenue (+25.3% YoY), -$11.2M in net income, and $6.4M in free cash flow against $70.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LFMD trading relative to its 50-day, 200-day, and 52-week technical levels?

LFMD last traded at $2.32 (+4.04% on volume of 739,738 shares), positioning the stock -17.73% below its 50-day simple moving average ($2.82) and -36.61% below its 200-day simple moving average ($3.66). Across its 52-week range of $2.06 to $5.96, LFMD sits at the 6.7% percentile with a 14-day RSI of 38.8 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($2.04 to $2.60).

LFMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is LifeMD Inc. (LFMD)?

In FY 2025 (10-K), LFMD converted $194.1M of revenue into a 85.7% gross margin, 0% operating margin, and $6.4M in free cash flow (3.3% FCF margin).

Direct Sub-Reports: LFMD RQD Cockpit LFMD 12M Forecast LFMD Earnings & Move LFMD Dividends & DRIP LFMD Insiders & 13F LFMD Whale Options LFMD Profit Sankey LFMD News & Why